For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chron...

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...

Mango season is here, bringing joy and questions for diabetics. Celebrity nutritionist Luke Coutinho offers guidance. He explains that mang...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

Emcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti-diabetic prod...

These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet. The ...

India's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...

In a grim reminder of the rise of lifestyle diseases, anti-diabetic molecule has for the first time become the largest-selling formulation ...